Literature DB >> 23388418

HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis.

Jie Liu1, Li-Ping Zhu, Xu-Li Yang, He-Lang Huang, Dong-Qing Ye.   

Abstract

CONTEXT: The association between 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone mineral density (BMD) is controversial because of conflicting findings from previous studies. OBJECTIVE AND
DESIGN: The purpose of the present study was to evaluate the effect of statins on BMD reported in randomized and non-randomized controlled trials. We searched PubMed and Embase, using text, medical subject headings (MeSH) and keywords "bone mineral density" and "statins" or "HMG-CoA reductase inhibitors". Our last PubMed and Embase queries were updated to August 2012. Data on participants, interventions, and outcomes from each study were abstracted independently by two authors.
RESULTS: Five case-control studies, six cohort studies and four randomized controlled trials (RCTs) met the inclusion criteria. Included studies involved 34,877 subjects (3824 in the intervention group and 31,053 in the control group) in 12 different countries with ages ranging from 44 to 66 years. Statins significantly increased BMD at lumbar spine [standardized mean difference (SMD) 0.15, 95% CI 0.09-0.22], total hip (SMD 0.22, 95% CI 0.17-0.27) and femoral neck (SMD 0.19, 95% CI 0.09-0.29). We carried out subgroup analyses on selected populations of the cohorts. Statistically significant increases were also observed in the lumbar spine (SMD 0.12, 95% CI 0.04-0.21), total hip (SMD 0.23, 95% CI 0.17-0.28) and femoral neck BMD (SMD 0.22, 95% CI 0.08-0.36).
CONCLUSION: The results of this study suggest that statins may help improve and maintain BMD at the lumbar spine, hip and femoral neck, especially in Caucasians and Asians. It also provides justification for prospective RCTs to evaluate the possible role of statins in BMD in different ethnic populations, such as Latin American and Africans.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23388418     DOI: 10.1016/j.bone.2013.01.044

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  16 in total

1.  Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

2.  STATINS AND BONE HEALTH: A MINI REVIEW.

Authors:  Leslie R Morse; Jennifer Coker; Ricardo A Battaglino
Journal:  Actual osteol       Date:  2018 Jan-Apr

3.  Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-16       Impact factor: 2.205

4.  Wheelchair use and lipophilic statin medications may influence bone loss in chronic spinal cord injury: findings from the FRASCI-bone loss study.

Authors:  L R Morse; N Nguyen; R A Battaglino; A J Guarino; D R Gagnon; R Zafonte; E Garshick
Journal:  Osteoporos Int       Date:  2016-07-13       Impact factor: 4.507

Review 5.  Efficacy of statins for osteoporosis: a systematic review and meta-analysis.

Authors:  T An; J Hao; S Sun; R Li; M Yang; G Cheng; M Zou
Journal:  Osteoporos Int       Date:  2016-11-25       Impact factor: 4.507

6.  Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model.

Authors:  Peter Orendáš; Peter Kubatka; Bianka Bojková; Monika Kassayová; Karol Kajo; Desanka Výbohová; Peter Kružliak; Martin Péč; Marián Adamkov; Andrea Kapinová; Katarína Adamicová; Vladimíra Sadloňová; Martina Chmelová; Nadežda Stollárová
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

7.  Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.

Authors:  Jessica M Peña; Sara Aspberg; Jean MacFadyen; Robert J Glynn; Daniel H Solomon; Paul M Ridker
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

8.  Genetic Sharing with Cardiovascular Disease Risk Factors and Diabetes Reveals Novel Bone Mineral Density Loci.

Authors:  Sjur Reppe; Yunpeng Wang; Wesley K Thompson; Linda K McEvoy; Andrew J Schork; Verena Zuber; Marissa LeBlanc; Francesco Bettella; Ian G Mills; Rahul S Desikan; Srdjan Djurovic; Kaare M Gautvik; Anders M Dale; Ole A Andreassen
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

9.  The Effects of Tocotrienol and Lovastatin Co-Supplementation on Bone Dynamic Histomorphometry and Bone Morphogenetic Protein-2 Expression in Rats with Estrogen Deficiency.

Authors:  Kok-Yong Chin; Saif Abdul-Majeed; Norazlina Mohamed; Soelaiman Ima-Nirwana
Journal:  Nutrients       Date:  2017-02-15       Impact factor: 5.717

Review 10.  Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-compliant Systematic Review and Meta-Analysis.

Authors:  Zongze Wang; Ying Li; Fengxin Zhou; Zhe Piao; Jian Hao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.